New and old genes associated with topotecan resistance development in ovarian cancer cell lines

25Citations
Citations of this article
34Readers
Mendeley users who have this article in their library.

Abstract

Background: Low effectiveness of chemotherapy in ovarian cancer results from development of drug resistance. Topotecan is a drug used as second-line chemotherapy for this cancer type. We analyzed development of topotecan resistance in ovarian cancer cell lines. Materials and Methods: A chemosensitivity assay, MTT test, was performed to assess drug resistance. Quantitative polymerase chain reaction (Q-PCR) assays were performed to determine ABCB1, ABCG2, ALDH1A1, IFIH1, SAMD4 and EPHA3 gene expression. Results: We observed dose-dependent responses to topotecan. In all topotecan-resistant cell lines an overexpression of ABCG2, IFIH1 and SAMD4 genes was observed. Expression of ABCB1 gene was observed in one cell line. Expression of ALDH1A1 was up-regulated in A2780 and down-regulated in SKOV-3-resistant cell lines. Short-time exposure led to similar patterns of gene expression for the investigated genes. Conclusion: Expression of ABCG2 and ABCB1 genes plays the most important role in topotecan resistance. The role of other investigated genes seems to be complementary.

Cite

CITATION STYLE

APA

Klejewski, A., Świerczewska, M., Zaorska, K., Brązert, M., Nowicki, M., Zabel, M., & Januchowski, R. (2017). New and old genes associated with topotecan resistance development in ovarian cancer cell lines. Anticancer Research, 37(4), 1625–1636. https://doi.org/10.21873/anticanres.11493

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free